TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Correct answers to the neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychological tests reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurophysiological tests EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurophysiological tests MEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurophysiological tests MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in weekly SCBM frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC)
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast to Noise Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motion Artifact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of the Ascending Aorta and Coronary Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracellular water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients in need for hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of hospitalization and ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: The need for mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of COVID-19 disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFA-100 closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of hypertensive disorder of pregnancy (HDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Inter/intra examiner repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incision Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Who Completed Interviews Regarding PAP Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sedation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time period between beginning of labor induction to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Preterm Birth Rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Primary outcome measurement not provided
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Number of newborn provided qualitative images for MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ad libitum food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to complete ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in self reported medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained virologic response (SVR) 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Grade II-IV intraventricular hemorrhage/periventricular leukomalacia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function Inhibition Measure 1: Flanker Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Function Measure: Updating Verbal Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair Stands: Change in Lower-body Muscular Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Numerical Analog Scale Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic response (reduction in Serum Alkaline Phosphatase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Subfield Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular and Non-Ocular Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HAM-A Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of the second stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Net whole-body protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Detection of HSV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive Percent Agreement of Detection of HSV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Negative Percent Agreement of Detection of HSV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Participants Who Achieve 50% Reduction in Number of Cigarettes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Death, Myocardial (re-) Infarction, or Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Vertical buccal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: global gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Clinical Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of contrast enhanced ultrasound in predicting benign vs. malignant histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of arterial blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vertigo Symptoms Score (VSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients needing 5 injections or less
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual Analog Scale of Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer agreement in the interpretation of CXRs for ARDS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to transplant
Endpoint domain: Mortality/survival
Primary endpoint: Self Reported Knee Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response (complete and partial) as assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of glucose readings within range of 70-180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of glucose readings below 54 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with EBV DNA copies/ml plasma higher than 50,000
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with signs of a post-transplant lymphoproliferative disorder (PTLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with adverse events (AEs), adverse reactions (ARs), serious adverse events (SAEs), serious adverse reactions (SARs) and suspected unexpected serious adverse reaction (SUSARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Adherence to Antihypertensives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: İsokinetic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABT-436 drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety labs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of intradialytic hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway Blood Flow Reactivity (Delta Qaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geographic miss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of catheter-related bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in log10 HIV-1 RNA from baseline to Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 2, 3, and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: safety and efficacy of MF101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated infusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Assessment of the Speaker's Evaluation of Stuttering (OASES) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: grading of filtering bleb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact of itch on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: days missing at work
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Residual neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of complete cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prognostic value of the IL-33/ST2 axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of inflammatory process in treated neurofibromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Psoriasis Area and Severity Index (PASI) Score at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Dermatology Life Quality Index (DLQI) Score at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rate of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: ocular and systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With R0 Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uncorrected Distance Vision Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Distance Vision Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trough forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: exercise function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-Proficiency (TTP) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implementation Effectiveness Index (IEI) Score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Level of Sustainment (LOS) Score
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients treated based on molecular tumor profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Hematological or Biochemical Laboratory Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: CRP-level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of ALT normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in P100 VEP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in visual analog scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of the arm, shoulder and hand questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-Rated Wrist Evaluation scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: UCLA-Post Traumatic Stress Disorder-Reaction Index-DSM-IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Stress Disorder Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lumbar Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of musculoskeletal disorders (MSDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tooth wear following BEWE index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hemoglobin A1c (A1C) < 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child's Mean Percent Days Under-immunized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with a correctly changed treatment plan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of metastatic lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of missed metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Condom protected penile-vaginal Sex Acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Used Other Birth Control Methods
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma concentrations of canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal threshold of glucose (RTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: salvage of patients resistant to initial treatment
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Able to Self-administer Injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of People With Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Interferon gamma release assay (IGRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vitamin D response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 25(OH)D response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success obtaining watertight closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood analysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation of ANSS and ANSSi with LF/HF and baroreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Superficial or Deep Surgical Site Infections (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Craving to Use Alcohol Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of pre-defined, serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction With Colposcopy Visit Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction With Colposcopy Information and Diagnosis Education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum levels of Vascular endothelial growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum levels of CD 133
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of pain in nine regions of the body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intensity of pain in nine regions of the body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Markedly Abnormal Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for E2511 on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting blood lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pouch function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mood as Evaluated by the Overall Bipolarity Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Triglyceride (TG) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histologically confirmed cervical intra-epithelial lesions grade 2 (CIN2) or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Keratometric values (OPD-Scan)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratometric values (Pentacam)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score in 28 Joints (DAS28) at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Remission Based on DAPSA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Month 36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Suturing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of acoustic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to advancement to full diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Six Month Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: One Year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Two Year Overall Survival
Endpoint domain: Mortality/survival